Autopsy report · NCT02277522

CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

“unable to meet enrollment goal”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 8 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

University of Pennsylvania

Sponsor type

University, hospital or other

Conditions

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis

Interventions

RNA anti-CD19 CAR T cells

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Mechanical vs. Radiofrequency-Based Debridement in the Treatment of Articular Cartilage Lesions
  “Unable to meet enrollment goals” (97% match in meaning)
• Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
  “unable to meet the target enrollment goal” (91% match in meaning)
• Cervical Ripening in Postmenopausal Women
  “not able to meet enrollment” (89% match in meaning)
• Hearing Resources and Outcomes in the Emergency Department (HERO-ED)
  “Did not meet enrollment” (81% match in meaning)
• An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
  “Insufficient enrollment” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.